ArticleBritish journal of anaesthesia2026
Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain.
Article in British journal of anaesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erdosteine Provides Effective Analgesia in Inflammatory Pain Without Impairing Pain Resolution: A Preclinical Comparison With Non-Steroidal Anti-Inflammatory Drugs.European journal of pain (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic postsurgical pain (CPSP) affects 5-85% of patients, depending on the surgery type, with minimal treatment options. A previous study showed that immune response inhibition by dexamethasone (DEXA) or NSAIDs in inflammatory pain assays in mice leads to pain prolongation, which can be reversed by injection of neutrophils or neutrophil-released S100A8/A9 proteins. Here we tested whether DEXA or NSAIDs similarly lead to prolonged pain in the mouse paw incisional assay, and if prostaglandin (PG) receptor agonists can prevent and resolve this pain through upregulation of S100A8/A9 in myeloid cells.
methodsCD-1 mice underwent plantar incision and were treated with DEXA, diclofenac, or saline. PG agonists (beraprost, treprostinil, or misoprostol) were administered postsurgery. Mechanical withdrawal thresholds were measured before and at multiple time points after incision injury. Neutrophils were depleted to confirm their involvement. Pathway validation was conducted using STAT3 and S100A8/A9 inhibitors and a STAT3 activator.
resultsSaline-treated mice recovered within 2 weeks, whereas DEXA-treated mice experienced prolonged hyperalgesia for >10 weeks. PG agonists both prevented and reversed the DEXA-induced hyperalgesia. Depletion of neutrophils in DEXA-treated mice impaired the effect of treprostinil. Inhibiting STAT3 or S100A8/A9 delayed recovery, whereas STAT3 activation mimicked treprostinil's effect. Diclofenac produced similar effects on pain duration as DEXA, also in a treprostinil-reversible manner.
conclusionsWe show that prostaglandin agonists can produce a surprising analgesic effect. Prostaglandin receptor agonists show promise in preventing and resolving CPSP by upregulating S100A8/A9 through the PKA-STAT3 pathway in innate immune cells, suggesting a new therapeutic approach for chronic postsurgical pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.